---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000217"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T21:49:06.669180+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Recursion completes Exscientia acquisition; issues 102M shares, names new CFO

## Summary
- Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
- Exscientia ADSs (EXAI) delisted from Nasdaq; equity awards converted to Recursion options/RSUs using Exchange Ratio.
- CFO Michael Secora steps down; Ben Taylor (Exscientia's former CFO) appointed CFO of Recursion and President of Recursion UK.
- COO Tina Marriott transitions to Executive Advisor; CEO Chris Gibson adds President role; David Hallet named CSO; other exec promotions.
- Board expands to 8; Franziska Michor appointed Class II director. 2024 Inducement Equity Plan adopted, reserving 17.5M shares.

## SEC filing metadata
- accession: 0001601830-24-000217
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 5.02, 7.01, 8.01, 9.01, 6.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/rxrx-20241119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000217
- JSON: https://secwatch.observer/filing/0001601830-24-000217.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000217.txt

## Source-grounded claims
- claim_id: 68fa937456
  claim: Michael Secora changed role as Chief Financial Officer at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: Michael Secora On November 20, 2024, the Company announced that Michael Secora (“Dr. Secora”), Chief Financial Officer of the Company, will be transitioning from his role as Chief Financial Officer, effective as of November 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm
- claim_id: 6de626c02f
  claim: Franziska Michor was appointed as Class II Director at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: the Board increased the number of members of the Board from 7 to 8 and appointed Franziska Michor, Ph.D., (“Dr. Michor”) as a Class II Director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm
- claim_id: 9c574936b8
  claim: Ben Taylor was appointed as Chief Financial Officer of the Company and President of Recursion UK at RECURSION PHARMACEUTICALS, INC..
  evidence_excerpt: Ben Taylor On November 20, 2024, the Board appointed Ben Taylor (“Mr. Taylor”), age 47, as Chief Financial Officer of the Company and President of Recursion UK, effective as of November 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.